A detailed history of Janus Henderson Group PLC transactions in Argenx Se stock. As of the latest transaction made, Janus Henderson Group PLC holds 2,479,207 shares of ARGX stock, worth $1.5 Billion. This represents 0.72% of its overall portfolio holdings.

Number of Shares
2,479,207
Previous 2,468,232 0.44%
Holding current value
$1.5 Billion
Previous $1.06 Billion 26.67%
% of portfolio
0.72%
Previous 0.58%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$434.22 - $551.9 $4.77 Million - $6.06 Million
10,975 Added 0.44%
2,479,207 $1.34 Billion
Q2 2024

Aug 14, 2024

BUY
$356.01 - $451.55 $89.6 Million - $114 Million
251,584 Added 11.35%
2,468,232 $1.06 Billion
Q1 2024

May 15, 2024

BUY
$356.95 - $413.29 $157 Million - $182 Million
439,889 Added 24.76%
2,216,648 $873 Million
Q4 2023

Feb 14, 2024

BUY
$338.91 - $506.01 $104 Million - $155 Million
305,621 Added 20.77%
1,776,759 $676 Million
Q3 2023

Nov 14, 2023

SELL
$369.35 - $548.43 $115 Million - $171 Million
-312,315 Reduced 17.51%
1,471,138 $723 Million
Q2 2023

Aug 14, 2023

SELL
$360.14 - $422.58 $4.09 Million - $4.8 Million
-11,357 Reduced 0.63%
1,783,453 $695 Million
Q1 2023

May 15, 2023

BUY
$334.23 - $403.65 $274 Million - $331 Million
820,090 Added 84.14%
1,794,810 $669 Million
Q4 2022

Feb 14, 2023

BUY
$342.17 - $402.31 $141 Million - $166 Million
412,435 Added 73.35%
974,720 $369 Million
Q3 2022

Nov 14, 2022

SELL
$343.2 - $395.75 $1.35 Million - $1.56 Million
-3,931 Reduced 0.69%
562,285 $199 Million
Q2 2022

Aug 15, 2022

SELL
$269.58 - $378.88 $11.6 Million - $16.3 Million
-42,935 Reduced 7.05%
566,216 $215 Million
Q1 2022

May 16, 2022

BUY
$254.45 - $351.06 $4.7 Million - $6.49 Million
18,490 Added 3.13%
609,151 $192 Million
Q4 2021

Feb 14, 2022

BUY
$272.01 - $353.03 $18.4 Million - $23.9 Million
67,723 Added 12.95%
590,661 $207 Million
Q3 2021

Nov 16, 2021

BUY
$295.0 - $350.58 $7.34 Million - $8.72 Million
24,878 Added 4.99%
522,938 $158 Million
Q2 2021

Aug 16, 2021

BUY
$257.11 - $319.92 $11.3 Million - $14 Million
43,772 Added 9.64%
498,060 $150 Million
Q1 2021

May 17, 2021

BUY
$268.3 - $380.31 $40.7 Million - $57.7 Million
151,667 Added 50.12%
454,288 $125 Million
Q4 2020

Feb 16, 2021

BUY
$248.13 - $308.36 $14.8 Million - $18.4 Million
59,657 Added 24.55%
302,621 $89 Million
Q3 2020

Nov 16, 2020

SELL
$215.51 - $272.51 $11.6 Million - $14.6 Million
-53,683 Reduced 18.1%
242,964 $63.8 Million
Q2 2020

Aug 14, 2020

SELL
$127.44 - $232.72 $285,720 - $521,758
-2,242 Reduced 0.75%
296,647 $66.8 Million
Q1 2020

May 14, 2020

SELL
$108.83 - $165.23 $3.78 Million - $5.73 Million
-34,708 Reduced 10.4%
298,889 $39.4 Million
Q4 2019

Feb 18, 2020

BUY
$106.59 - $164.21 $3.79 Million - $5.83 Million
35,533 Added 11.92%
333,597 $53.5 Million
Q3 2019

Nov 14, 2019

SELL
$113.31 - $150.51 $1.56 Million - $2.07 Million
-13,730 Reduced 4.4%
298,064 $34 Million
Q2 2019

Jul 31, 2019

SELL
$115.0 - $141.58 $5.88 Million - $7.24 Million
-51,124 Reduced 14.09%
311,794 $44.1 Million
Q1 2019

Apr 30, 2019

SELL
$98.85 - $134.59 $7.72 Million - $10.5 Million
-78,146 Reduced 17.72%
362,918 $45.3 Million
Q4 2018

Feb 06, 2019

SELL
$63.81 - $109.82 $3.36 Million - $5.77 Million
-52,585 Reduced 10.65%
441,064 $42.4 Million
Q3 2018

Nov 09, 2018

BUY
$75.5 - $96.63 $4.01 Million - $5.13 Million
53,070 Added 12.05%
493,649 $37.4 Million
Q2 2018

Aug 10, 2018

BUY
$74.84 - $100.16 $333,561 - $446,413
4,457 Added 1.02%
440,579 $36.5 Million
Q1 2018

May 14, 2018

SELL
$56.95 - $85.19 $7.36 Million - $11 Million
-129,163 Reduced 22.85%
436,122 $35.1 Million
Q4 2017

Feb 09, 2018

BUY
$22.57 - $63.56 $12.8 Million - $35.9 Million
565,285
565,285 $35.7 Million

Others Institutions Holding ARGX

About ARGENX SE


  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $33.5B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track Janus Henderson Group PLC Portfolio

Follow Janus Henderson Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Janus Henderson Group PLC with notifications on news.